• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

4.900 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AtaiBeckley Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Small-Cap Medical Stocks: ATAI, CMPS, NDRA, PBM in Focus as U.S. Policy Accelerates Psychedelic Research
April 20, 2026
Via AB Newswire
News headline image
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
March 24, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
March 17, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
March 10, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!
March 09, 2026
Via AB Newswire
News headline image
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
March 06, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
March 03, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
February 26, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley To Host Virtual Investor Day on March 6, 2026
February 20, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
February 19, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley To Participate in Upcoming Investor Conferences
February 17, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
January 16, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
January 08, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Completes Redomiciliation to the United States
December 30, 2025
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
December 23, 2025
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio
December 11, 2025
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London
November 13, 2025
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 12, 2025
AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration 
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression
November 10, 2025
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies
November 05, 2025
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
October 20, 2025
Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Pricing of Public Offering of Common Shares
October 16, 2025
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Proposed Public Offering of Common Shares
October 16, 2025
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
October 16, 2025
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
September 23, 2025
From atai Life Sciences
Via GlobeNewswire
MissionIRNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Jumps as ARK Invest Buys $49.7M Stake, Trims Roku and Tempus AI
September 19, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
atai Life Sciences Awarded Grant from the National Institutes of Health
September 18, 2025
5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder 
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in September Investor Conferences
August 28, 2025
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
August 14, 2025
From atai Life Sciences
Via GlobeNewswire
News headline image
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
July 25, 2025
From atai Life Sciences
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap